Page last updated: 2024-11-05

trihexyphenidyl and Marfan Syndrome

trihexyphenidyl has been researched along with Marfan Syndrome in 2 studies

Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Marfan Syndrome: An autosomal dominant disorder of CONNECTIVE TISSUE with abnormal features in the heart, the eye, and the skeleton. Cardiovascular manifestations include MITRAL VALVE PROLAPSE, dilation of the AORTA, and aortic dissection. Other features include lens displacement (ectopia lentis), disproportioned long limbs and enlarged DURA MATER (dural ectasia). Marfan syndrome (type 1) is associated with mutations in the gene encoding FIBRILLIN-1 (FBN1), a major element of extracellular microfibrils of connective tissue. Mutations in the gene encoding TYPE II TGF-BETA RECEPTOR (TGFBR2) are associated with Marfan syndrome type 2.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rao, NP1
Loganathan, S1
Prakash, O1
Varghese, M1
Blackburn, JS1
Cirillo, ML1

Other Studies

2 other studies available for trihexyphenidyl and Marfan Syndrome

ArticleYear
Use of electroconvulsive therapy for schizophrenia with comorbid Marfan syndrome.
    The journal of ECT, 2009, Volume: 25, Issue:4

    Topics: Adult; Antipsychotic Agents; Catatonia; Electroconvulsive Therapy; Female; Humans; Marfan Syndrome;

2009
Clinical reasoning: A 13-year-old boy presenting with dystonia, myoclonus, and anxiety.
    Neurology, 2012, Mar-13, Volume: 78, Issue:11

    Topics: Adolescent; Anti-Dyskinesia Agents; Anxiety; Diagnosis, Differential; Dystonia; Genetic Testing; Han

2012